Stockscreener 앱 받기
71.66
1.24%
0.88
전일 마감가:
$70.78
열려 있는:
$70.85
하루 거래량:
2.86M
Relative Volume:
0.71
시가총액:
$28.72B
수익:
$4.03B
순이익/손실:
$576.20M
주가수익비율:
50.11
EPS:
1.43
순현금흐름:
$630.70M
1주 성능:
+4.51%
1개월 성능:
-2.57%
6개월 성능:
-2.42%
1년 성능:
-48.08%
1일 변동 폭
$70.36
$72.28
1주일 범위
$65.11
$72.28
52주 변동 폭
$57.52
$138.81
덱스컴 Stock (DXCM) Company Profile
명칭
Dexcom Inc
전화
(858) 200-0200
주소
6340 SEQUENCE DRIVE, SAN DIEGO, CA
DXCM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
71.66 | 28.72B | 4.03B | 576.20M | 630.70M | 1.43 |
|
ABT
Abbott Laboratories
|
128.85 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
101.90 | 138.41B | 17.55B | 2.03B | 2.37B | 1.37 |
|
SYK
Stryker Corp
|
365.06 | 129.62B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
84.16 | 107.92B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
76.04 | 40.53B | 5.54B | 4.18B | 259.90M | 7.00 |
덱스컴 Stock (DXCM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-03 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 개시 | Redburn Atlantic | Neutral |
| 2024-03-12 | 개시 | RBC Capital Mkts | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-04-17 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 개시 | UBS | Buy |
| 2023-01-26 | 개시 | Wolfe Research | Outperform |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-15 | 개시 | Bernstein | Outperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-01-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-28 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2021-01-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-10-02 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 재확인 | Piper Sandler | Overweight |
| 2020-05-14 | 개시 | Wells Fargo | Equal Weight |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-11-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-10-23 | 개시 | Stifel | Buy |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-19 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-09-12 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 재확인 | Canaccord Genuity | Buy |
| 2018-07-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
| 2018-05-03 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-04 | 개시 | Goldman | Sell |
| 2018-04-04 | 개시 | Guggenheim | Neutral |
| 2018-03-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 재확인 | Wedbush | Outperform |
모두보기
덱스컴 주식(DXCM)의 최신 뉴스
Press Release Distribution & PR Platform - ACCESS Newswire
DexCom Inc (DXCM) Stock Price Up 5.21% on Apr 24 - GuruFocus
Kuehn Law Encourages Investors of DexCom, Inc. to Contact Law Firm - The Malaysian Reserve
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders - GlobeNewswire
FDA Approves Dexcom G5® Mobile Continuous Glucose Monitoring System - ADVFN
Dexcom Launches First Nationwide Search for College Athletes With Diabetes to Join Season Four of Dexcom U - Business Wire
Stocks Update From Health Care Sector -- DexCom, Alkermes, BioCryst Pharmaceuticals, Anacor Pharmaceuticals and Endologix - ADVFN
DXCMDexCom Reports Second Quarter 2018 Financial Results - ADVFN
Dexcom G6 Real-Time CGM System Now Accessible to Any Eligible Client Managing Diabetes With Insulin Through NIHB - ADVFN
DexCom, Inc. (NASDAQ:DXCM) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating DexCom, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - TradingView
Dexcom, Beyond Type 2 and Retta Establish National Glucose Awareness Week to Close the Glucose Knowledge Gap - Investegate
DexCom Execs Sued For Allegedly Misleading Growth Claims - Law360
DexCom (NasdaqGS:DXCM) Gains FDA Clearance For Dexcom G7 System - Yahoo Finance
Alert on DexCom from law firm's press release withdrawn - marketscreener.com
RBC Cuts Price Target on DexCom to $100 From $115, Keeps Outperform Rating - marketscreener.com
BTIG Adjusts DexCom (DXCM) Price Target Ahead of MedTech Q1 Resu - GuruFocus
FDA Clears Dexcom G7 15 Day for Continuous Glucose Monitoring - Clinical Advisor
BTIG Adjusts DexCom (DXCM) Price Target Ahead of MedTech Q1 Results | DXCM Stock News - GuruFocus
DexCom Shares May Rise as G7 15-Day CGM System Gets FDA Clearance - MSN
FDA clears Dexcom G7 15 Day - BioWorld MedTech
What to Expect From DexCom's Next Quarterly Earnings Report - Nasdaq
What Does the Market Think About DexCom? - Benzinga
DexCom signals 14% revenue growth target for 2025 with new product launches and expanded coverage - MSN
What To Expect From DexCom's Next Quarterly Earnings Report - Barchart.com
DexCom (DXCM) Faces Market Challenges Amid Strategic Changes - GuruFocus
DexCom (DXCM) Anticipates Growth Driven by Strategic Initiatives - GuruFocus
DexCom (DXCM) Gains on FDA Approval for G7 15 Day Monitoring Sys - GuruFocus
FDA clears Dexcom G7 15-Day continuous glucose monitor - TechTarget
Mizuho Initiates Coverage of DexCom (XTRA:DC4) with Outperform Recommendation - Nasdaq
Dexcom G7 15 Day CGM system cleared by FDA for adults - Investing.com South Africa
Dexcom G7 15 Day CGM System Cleared by FDA - Patient Care Online
DexCom (DXCM) Faces Investor Backlash After Disappointing Earnings ReportHagens Berman - ACCESS Newswire
Dexcom nets FDA clearance for 15-day CGM - MedTech Dive
Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With DexcomPanhandle - Panhandle - News Channel
FDA Approves New DexCom Diabetes Device - Yahoo Finance
FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch - Benzinga
덱스컴 (DXCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
0.60%
자본화:
|
볼륨(24시간):